Neurocrine Biosciences
NBIX
NBIX
345 hedge funds and large institutions have $10.9B invested in Neurocrine Biosciences in 2018 Q3 according to their latest regulatory filings, with 90 funds opening new positions, 94 increasing their positions, 115 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
18% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 115
28% less call options, than puts
Call options by funds: $60.8M | Put options by funds: $84.1M
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Holders
345
Holding in Top 10
4
Calls
$60.8M
Puts
$84.1M
Top Buyers
| 1 | +$40.7M | |
| 2 | +$32.6M | |
| 3 | +$32.6M | |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$31.7M |
| 5 |
Two Sigma Advisers
New York
|
+$29.3M |
Top Sellers
| 1 | -$160M | |
| 2 | -$102M | |
| 3 | -$64.6M | |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$55.7M |
| 5 |
HM
HealthCor Management
New York
|
-$47.2M |